NetworkNewsBreaks – Processa Pharmaceuticals Inc
Post# of 40
(Total Views: 235)
Posted On: 10/13/2020 3:48:43 PM
NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Serial Entrepreneur as New Chief Operating Officer
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed several life science organizations and served as a senior executive in those organizations, will be taking over that role. Floyd is well suited for the new position as many of the companies he has been involved in were focused on the development of products to treat infectious and rare diseases as well as the development of oncology drugs. Most recently, he co-founded Elion Oncology which licensed PCS6422 to Processa. In addition, he founded Neurologic, an early-stage enterprise that in-licensed technology from the NIH for a diagnostic test for Alzheimer’s disease. He was also CEO at the North American subsidiary of Arpida Ltd., overseeing the organization of the phase 3 program for the NDA submission of an MRSA drug. And at Gentium, SpA, he led U.S. efforts to remediate the NDA for defibrotide. “Adding Mike to our leadership team will enable me to spend more time focusing on our long-term strategic direction and our pipeline,” Processa CEO and chairman David Young, MD, stated in the press release. “Mike is a proven life science entrepreneur with a demonstrated track record of successfully delivering results. He has the leadership capabilities we are looking for to help us grow Processa.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed several life science organizations and served as a senior executive in those organizations, will be taking over that role. Floyd is well suited for the new position as many of the companies he has been involved in were focused on the development of products to treat infectious and rare diseases as well as the development of oncology drugs. Most recently, he co-founded Elion Oncology which licensed PCS6422 to Processa. In addition, he founded Neurologic, an early-stage enterprise that in-licensed technology from the NIH for a diagnostic test for Alzheimer’s disease. He was also CEO at the North American subsidiary of Arpida Ltd., overseeing the organization of the phase 3 program for the NDA submission of an MRSA drug. And at Gentium, SpA, he led U.S. efforts to remediate the NDA for defibrotide. “Adding Mike to our leadership team will enable me to spend more time focusing on our long-term strategic direction and our pipeline,” Processa CEO and chairman David Young, MD, stated in the press release. “Mike is a proven life science entrepreneur with a demonstrated track record of successfully delivering results. He has the leadership capabilities we are looking for to help us grow Processa.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)